Merck KGaA to provide extensive biotech support to GenScript in China

19 March 2019

Darmstadt, Germany-based Merck KGaA (MRK: DE) has entered into a strategic alliance with Chinese biotech company GenScript (HKG: 1548), based around plasmid and viral vector manufacturing.

Headquartered in Nanjing, China, GenScript is seeking to expand into immunotherapy and contract development and manufacturing organization (CDMO). The firm has multiple manufacturing centers in Asia, Europe and the USA.

The firm has signed a non-binding memorandum of understanding with Merck, launching an alliance aimed at accelerating the industrialization and commercialization of cell and gene therapies in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK